Company: ARVN
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049527
Chunk: 146

Company: ARVINAS, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 146
---
 of laboratory supplies and developing preclinical studies and clinical trial materials; 

•facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs; 

•costs incurred in the development of intellectual property; and

•third-party licensing fees. 

We expense research and development costs as incurred. 

36

Table o    f Contents

We typically use our employee and infrastructure resources across our development programs, and as such, do not track all of our internal research and development expenses on a program-by-program basis. The following table summarizes our research and development expenses for the three and nine months ended September 30, 2025 and 2024:

For the Three Months EndedSeptember 30,For the Nine Months EndedSeptember 30,(dollars in millions)2025202420252024Program-specific external expense:Vepdegestrant (ARV-471) (*)14.2 19.6 53.4 63.8 ARV-1025.0 4.5 15.3 7.5 ARV-806 5.1 0.8 7.7 1.1 ARV-3932.6 1.7 7.7 4.6 Bavdegalutamide (ARV-110)0.3 2.7 2.3 6.8 Luxdegalutamide (ARV-766)— 4.7 — 17.9 Other programs0.3 — 2.8 — Total program-specific external expense27.5 34.0 89.2 101.7 Non program-specific external expense12.8 13.7 37.9 43.4 Unallocated internal expenseCompensation and related personnel expense(including stock-based compensation)21.6 35.8 88.6 110.4 Other research and development expense2.8 3.4 8.4 9.4 Total unallocated internal expense24.4 39.2 97.0 119.8 Total research and development expense$64.7 $86.9 $224.1 $264.9 

(*)    Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an